WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

In rural India, mycetoma—a painful, neglected disease from minor wounds—cripples workers, causing disability, poverty, and stigma. Delayed diagnosis and costly treatment worsen the crisis.

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

South Africa will buy lenacapavir using Global Fund money. Studies show it can stop infections entirely in young women. But ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The WHO has approved the use of a new drug to prevent HIV. The drug is called Lenacapavir, and what makes it unique is that ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...